Systemic Hypertension

Current Problems in Cardiology

Volumn 32, Issue 4, 2007, Pages 201-259

  Elliott, William J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EPLERENONE; FELODIPINE; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CLINICAL TRIAL; DISEASE CONTROL; ECONOMICS; EVALUATION; GERIATRICS; HOME MONITORING; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MATERNAL HYPERTENSION; PATHOPHYSIOLOGY; SYMPTOM; TREATMENT INDICATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; COSTS AND COST ANALYSIS; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 33947573552     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2007.01.002     Document Type: Article

References (179)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289 (2003) 2560-2572
2. Chobanian A.V., Bakris G.L., Black H.R., et al., National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
3. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
4. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) 85-151
5. Hoyert DL, Heron M, Murphy SL, et al. Deaths: Final data for 2003. www.cdc.gov/nchs/products/pubs/pubd/hestats/finaldeaths03/finaldeaths03.htm, 2006.
6. United States Renal Data System. USRDS 2003 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD, July 31, 2003. Also found at: www.usrds.org, accessed 21 February 06 at 19:28 CST.
7. Glover M.J., Greenlund K.J., Ayala C., et al. Racial/ethnic disparities in prevalence, treatment and control of hypertension-United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54 (2005) 7-9
8. Vasan R.S., Larson M.G., Leip E.P., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345 (2001) 1291-1297
9. Julius S., Nesbitt S.D., Egan B., et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med 354 (2006) 1685-1697
10. Whelton P.K., He J., Appel L.J., et al. Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Program. JAMA 288 (2002) 1882-1888
11. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R., and Prospective Studies Collaborative. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
12. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 45 (2005) 142-161
13. Staessen J.A., Gasowski J., Wang J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355 (2000) 865-872
14. Wang J.-G., Staessen J.A., Franklin S.S., et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 46 (2005) 907-913
15. Izzo Jr. J.L., Levy D., and Black H.R. Clinical advisory statement: Importance of systolic blood pressure in older Americans. Hypertension 35 (2000) 1021-1024
16. Franklin S.S., Jacobs M.J., Wong N.D., et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37 (2001) 869-874
17. Singer G.M., Izhar M., and Black H.R. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 40 (2002) 464-469
18. Jackson R., Lawes C.M.M., Bennett D.A., et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 365 (2005) 434-441
19. MacMahon S., Neal B., and Rodgers A. Hypertension-time to move on. Lancet 365 (2005) 1108-1109
20. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 320 (2000) 709-710
21. Grundy S.M., Becker D., Clark L.T., et al. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
22. Ogden L.G., He J., Lydick E., et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI Risk Stratification. Hypertension 34 (2000) 539-543
23. Giles T., Berk B., Black H.R., et al. Position paper: expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 7 (2005) 505-512
24. Whitworth J.A., World Health Organization, and International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21 (2003) 1983-1992
25. Zanchetti A., Cifkova R., Fagard R., et al., Guideline Committee. 2003 European Society of Hypertension-European Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 21 (2003) 1011-1053
26. Wallis E.J., Ramsay L.E., Haq I.U., et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 320 (2000) 671-676
27. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275 (1996) 1571-1576
28. Lee M.L., Rosner B.A., and Weiss S.T. Relationship of blood pressure to cardiovascular death: the effects of pulse pressure in the elderly. Ann Epidemiol 9 (1999) 101-107
29. van den Hoogen P.C.W., Feskens E.J.M., Nagelkerke N.J.D., et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 342 (2000) 1-8
30. Rogers A., MacMahon S., Yee T., and Clark T. Blood pressure, cholesterol, and stroke in eastern Asia: Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 352 (1998) 1801-1807
31. Staessen J.A., Wang J.G., and Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358 (2001) 1305-1315
32. Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 13 suppl 2 (2000) 3S-10S
33. Cheung B.M.Y., Ong K.L., Man Y.B., et al. Prevalence, awareness, treatment and control of hypertension: United States National Health and Nutrition Examination Survey, 2001-2002. J Clin Hypertens (Greenwich) 8 (2006) 93-98
34. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287 (2002) 1003-1010
35. Lloyd-Jones D.M., Evans J.C., Larson M.G., et al. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Hypertension 34 (1999) 381-385
36. Black H.R., Kuller L.H., O′Rourke M.F., et al. The first report of the Systolic and Pulse Pressure (SYPP) Working Group on systolic and pulse pressure. J Hypertens 17 suppl 5 (1999) S3-S14
37. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139 (2003) 244-252
38. Haider A.W., Larson M.G., Franklin S.S., et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138 (2003) 10-16
39. Hyman D.J., and Pavlik V.N. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 345 (2001) 479-486
40. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-203
41. Gueyffier F., Bulpitt C., Boissel J.-P., et al., INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 353 (1999) 793-796
42. Elliott W.J. Hypertension grand rounds: management of hypertension in the very elderly patient. Hypertension 44 (2004) 800-804
43. Jones C.A., and Nagpal S. An update: women, hypertension and therapeutic efficacy. Can J Cardiol 17 (2001) 1283-1289
44. Furberg C.D., Wright Jr. J.T., Davis B.R., et al., The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
45. Turnbull F., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
46. Lawes C.M., Bennett D.A., Feigin V.L., et al. Blood pressure and stroke: an overview of published reviews. Stroke 35 (2004) 776-785
47. Wassertheil-Smoller S., Psaty B., Greenland P., et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 292 (2004) 2849-2859
48. Hertz R.P., Unger A.N., Corneel J.A., et al. Racial disparities in hypertension prevalence, awareness and management. Arch Intern Med 165 (2005) 2098-2104
49. Brewster L.M., van Montfrans G.A., and Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 141 (2004) 614-627
50. Wright Jr. J.T., Bakris G.L., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 288 (2002) 2421-2431
51. Rehman S.U., Hutchison F.N., Hendrix K., et al. Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites. Arch Intern Med 165 (2005) 1041-1047
52. Erdine S. How well is hypertension controlled in Europe?. J Hypertens 18 (2000) 1348-1349
53. Julius S., Kjeldsen S., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
54. Weber M., Julius S., Kjeldsen K.E., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363 (2004) 2049-2051
55. Elliott W.J. Improving the cost-effectiveness of treating hypertension. In: Epstein M. (Ed). Calcium Antagonists in Clinical Medicine. 3rd Edition (2002), Hanley & Belfus, Inc, Philadelphia, PA 733-748
56. Elliott W.J. Economic considerations in the management of hypertension. In: Izzo Jr. J.L., and Black H.R. (Eds). Hypertension Primer. 3rd Edition (2003), Lippincott, Williams & Wilkins, Baltimore, MD 317-319
57. Oparil S., Zaman A., and Calhoun D.A. Pathogenesis of hypertension. Ann Intern Med 139 (2003) 761-776
58. Johnson R.J., Rodriguez-Iturbe B., Kang D.-H., et al. A unifying pathway for essential hypertension. Am J Hypertens 18 (2005) 431-440
59. Mendelsohn M.E. In hypertension, the kidney is not always the heart of the matter. J Clin Invest 115 (2005) 840-844
60. Cowley Jr. A.W., and Roman R.J. The role of the kidney in hypertension. JAMA 275 (1996) 1581-1589
61. O′Brien E. Has conventional syphgmomanometry ended with the banning of mercury?. Blood Press Monit 7 (2002) 37-40
62. Parati G., Asmar R., and Stergiou G.S. Self blood pressure monitoring at home by wrist devices: a reliable approach?. J Hypertens 20 (2002) 573-578
63. Staessen J.A., Den Hond E., Celis H., et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA 291 (2004) 955-964
64. Yarows S.A., Julius S., and Pickering T.G. Home blood pressure monitoring. Arch Intern Med 160 (2000) 1251-1257
65. Cappuccio F.P., Kerry S.M., Forbes L., et al. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ 329 (2004) 145
66. Perloff D., Sokolow M., Cowan R.M., et al. Prognostic value of ambulatory blood pressure measurements: Further analyses. J Hypertens 7 suppl 3 (1989) S3-S10
67. Imai Y., Ohkubo T., Tsuji I., et al. Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. Blood Press Monit 1 suppl 2 (1996) 51-58
68. Bobrie G., Chatellier G., Genes N., et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 291 (2004) 1342-1349
69. Ohkubo T., Imai Y., Tsuji I., et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens 16 (1998) 971-975
70. Rogers M.A., Small D., Buchan D.A., et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension. A randomized, controlled trial. Ann Intern Med 134 (2001) 1024-1032
71. Broege P.A., James G.D., and Pickering T.G. Management of hypertension in the elderly using home blood pressures. Blood Press Monit 6 (2001) 139-144
72. Campo C., Fernandez G., Gonzalez-Estaban J., et al., ESPADA Study Group. Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. Blood Press 9 (2000) 355-362
73. Leeman M.J., Lins R.L., Sternon J.E., et al. Effect of antihypertensive treatment on office and self-measured blood pressure: The Autodil study. J Human Hypertens 14 (2000) 525-529
74. O'Brien E., Asmar R., Beilin L., et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 21 (2003) 821-848
75. O'Brien E., Beevers G., and Lip G.Y.H. ABC of hypertension: blood pressure measurement: Part III-Automated sphygmomanometry: ambulatory blood pressure measurement. BMJ 322 (2001) 1110-1114
76. Tunis S, Kendall P, Londner M, et al. Medicare Coverage Policy-Decisions: Ambulatory Blood Pressure Monitoring (#CAG-00067N): Decision Memorandum. Washington, DC. Health Care Financing Administration, October 17, 2001. Found on the Internet at: www.hcfa.gov/coverage/8b3-ff2.htm; accessed 01 April 02 at 18:32 CST.
77. Staessen J.A., Thijs L., Fagard R., et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. JAMA 282 (1999) 589-596
78. Kario K., Pickering T.G., Matsuo T., et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 38 (2001) 852-857
79. Bur A., Herkner H., Vlcek M., et al. Classification of blood pressure levels by ambulatory blood pressure in hypertension. Hypertension 40 (2002) 817-822
80. Clement D.L., De Buyzere M.L., De Bacquer D.A., et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348 (2003) 2407-2415
81. White W.B., and Larocca G.M. Improving the utility of the nocturnal hypertension definition by using absolute sleep blood pressure rather than the "dipping" proportion. Am J Cardiol 92 (2003) 1439-1441
82. Staessen J.A., Bieniaszewski L., O'Brien E., et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension 29 (1997) 30-39
83. Lurbe E., Redon J., Kesani A., et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347 (2002) 797-805
84. Verdecchia P., Schillaci G., Borgioni C., et al. Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. J Hypertens 16 (1998) 1335-1343
85. Verdeccia P., Schillaci G., Reboldi G., et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 103 (2001) 2579-2584
86. Verdecchia P., Reboldi G., Porcellati C., et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. J Am Coll Cardiol 39 (2002) 878-885
87. Kario K., Eguchi K., Hoshide S., et al. U-curve relationship between orthostatic blood pressure change and silent cerebrovascular disease in elderly hypertensives: orthostatic hypertension as a new cardiovascular risk factor. J Am Coll Cardiol 40 (2002) 133-141
88. Kario K., Pickering T.G., Umeda Y., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107 (2003) 1401-1406
89. White W.B. Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med 348 (2003) 2377-2378
90. Ohkubo T., Imai Y., Tsuji I., et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 15 (1997) 357-364
91. Redon J., Campos C., Narciso M.L., et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 31 (1998) 712-718
92. Pierdomenico S.D., Bucci A., Constantini F., et al. Twenty-four hour autonomic nervous function in sustained and "white coat" hypertension. Am Heart J 140 (2000) 672-677
93. Moser M. White-coat hypertension: to treat or not to treat: a clinical dilemma [Editorial]. Arch Intern Med 161 (2001) 2655-2656
94. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of the white coat effect. Hypertension 29 (1997) 1218-1224
95. Verdecchia P., Reboldi G.P., Angeli F., et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 45 (2005) 203-208
96. Fagard R.H., Staessen J.A., Thijs L., et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 102 (2000) 1139-1144
97. Grossman E., Messerli F.H., and Neutel J.M. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. Arch Intern Med 160 (2000) 1905-1911
98. Hansson L., Smith D.H., Reeves R., et al. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 160 (2000) 1654-1658
99. Grimm Jr. R.H., Grandits G.A., Cutler J.A., et al., TOMHS Research Group. Relationships of quality of life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study (TOMHS). Arch Intern Med 157 (1997) 638-648
100. Wiklund I., Halling K., Ryden-Bergsten T., et al. Does lowering the blood pressure improve the mood?. Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 6 (1997) 357-364
101. Williams B., Poulter N.R., Brown M.J., et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 328 (2004) 634-640
102. Feldman R., and Canadian Hypertension Education Program. 2005 Canadian Hypertension Education Program recommendations: what are the new messages?. Perspect Cardiol 21 (2005) 30-34
103. van den Born B.J., Hulsman C.A., Hoekstra J.B., et al. Value of routine funduscopy in patients with hypertension: systematic review. BMJ 331 (2005) 73-76
104. Turner R., Holman R., Stratton I., et al., UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703
105. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
106. Abosaif N.Y., Arije A., Atray N.K., et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 5 suppl 1 (2004) S1-S290
107. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 113 (2006) 1213-1225
108. Taler S.J., Textor S.C., and Augustine J.E. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39 (2002) 982-988
109. Clarke R., Collins R., Lewington S., et al., Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288 (2002) 2015-2022
110. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
111. Lewis E.J., Hunsicker L.G., Clarke W.R., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 345 (2001) 851-860
112. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) Study Group. N Engl J Med 345 (2001) 861-869
113. Safian R.D., and Textor S.C. Medical progress: renal-artery stenosis. N Engl J Med 344 (2001) 431-442
114. Krijnen P., van Jaarsveld B.C., Steyerberg E.W., et al. A clinical prediction rule for renal artery stenosis. Ann Intern Med 129 (1998) 738-740
115. Krijnen P., Steyerberg E.W., Postma C.T., et al. Validation of a prediction rule for renal artery stenosis. J Hypertens 23 (2005) 1583-1588
116. Weinrauch L.A., and D′Elia J.A. Renal artery stenosis: "Fortuitous diagnosis," problematic therapy. [Editorial]. J Am Coll Cardiol 43 (2003) 1614-1616
117. Vasbinder G.B., Nelemans P.J., Kessels A.G., et al. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 135 (2001) 401-411
118. Vasbinder G.B.C., Nelemans P.J., Kessels A.G.H., et al., Renal Artery Diagnostic Imaging Study in Hypertension (RADISH) Study Group. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 141 (2004) 674-682
119. Bax L., Mali W.P., Buskens E., et al. The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal Artery. The STAR-study: rationale and study design. J Nephrol 16 (2003) 807-817
120. Bravo E.L. Pheochromocytoma. Cardiol Rev 10 (2002) 44-50
121. Lenders J.W., Eisenhofer G., Mannelli M., et al. Phaeochromocytoma. Lancet 366 (2005) 665-675
122. Kudva Y.C., Sawka A.M., and Young Jr. W.F. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endo Metab 88 (2003) 4533-4539
123. Kaplan N.M. Cautions over the current epidemic of primary hyperaldosteronism. Lancet 357 (2001) 953-954
124. Schwartz G.L., and Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51 (2005) 386-394
125. Lim P.O., Young W.F., and MacDonald T.M. A review of the medical treatment of primary hyperaldosteronism. J Hypertens 19 (2001) 353-361
126. Goodfriend T.L., and Calhoun D.A. Resistant hypertension, obesity, sleep apnea and aldosterone: theory and therapy. Hypertension 43 (2004) 518-524
127. Netzer N.C., Stoohs R.A., Netzer C.M., et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 131 (1999) 485-491
128. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. High prevalence of primary hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
129. Marin J.M., Carrizo S.J., Vicente E., et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure; an observational study. Lancet 365 (2005) 1046-1053
130. Neter J.E., Stam B.E., Kok F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42 (2003) 878-884
131. He F.J., and MacGregor G.A. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 16 (2002) 761-770
132. Whelton P.K., Cutler J.A., Appel L., and The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, Phase II. Arch Intern Med 157 (1997) 657-667
133. Whelton P.K., Appel L.J., Espeland M.A., et al., TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA 279 (1998) 839-846
134. Appel L.J., Champagne C.M., Harsha D.W., et al., Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 289 (2003) 2083-2093
135. Xin X., He J., Frontini M.G., et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 38 (2001) 1112-1117
136. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344 (2001) 3-9
137. Neaton J.D., Grimm Jr. R.H., Prineas R.J., et al. Treatment of Mild Hypertension Study: final results. JAMA 270 (1993) 713-724
138. Elliott W.J., and Black H.R. The Evidence-Base for Treatment of Hypertension. In: McInnes G.T. (Ed). Handbook of Hypertension, vol. 24: Clinical Pharmacology and Therapeutics of Antihypertensive Drugs (2007), Elsevier, New York, NY
139. Lindholm L.H., Carlberg B., and Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
140. Alderman M.A., Furberg C.D., Wright Jr. J.T., and Antihypertensive and Lipid-lowering treatment to prevent Heart Attack Trial Collaborative Research Group. Diuretic versus α-blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). Hypertension 42 (2003) 239-246
141. Staessen J.A., Wang J.-G., and Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 01 March 2003. J Hypertens 21 (2003) 1005-1076
142. Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
143. Psaty B.M., Lumley T., and Furberg C.D. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low dose diuretic therapies. JAMA 292 (2004) 43-44
144. Choi K., Chua D., and Elliott W.J. Chlorthalidone vs. other low-dose diuretics. [Letter]. JAMA 292 (2004) 1816-1817
145. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 82 (1990) 1616-1628
146. Khosla N., Elliott W.J., and Bakris G.L. Are chlorthalidone and hydrochorothiazide equivalent blood pressure-lowering medications?. [Commentary]. J Clin Hypertens (Greenwich) 7 (2005) 354-356
147. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
148. Burris J., Weir M., Oparil S., et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 263 (1990) 1507-1512
149. Lithell H., Hansson L., Skoog I., et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21 (2003) 875-886
150. Liu L., Zhang Y., Liu G., et al., FEVER Study Group. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23 (2005) 2157-2172
151. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) Study. BMJ 321 (2000) 1440-1444
152. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124
153. Stergiou G.S., Makris T., Papavasiliou M., et al. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 23 (2005) 883-889
154. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: the HOT Study Group. Lancet 351 (1998) 1755-1762
155. American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 27 suppl 1 (2004) S1-S153
156. Raikou M., Gray A., Briggs A., et al., U.K. Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 317 (1998) 720-726
157. Elliott W.J., Weir D.R., and Black H.R. Cost-effectiveness of lowering treatment goal of JNC VI for diabetic hypertensives. Arch Intern Med 160 (2000) 1277-1283
158. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 49 2 Suppl 2 (2007) S12-S154
159. Sarnak M.J., Greene T., Wang X., et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease study. Ann Intern Med 142 (2005) 342-351
160. Ruggenenti P., Perna A., Loriga G., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 365 (2005) 939-946
161. Casas J.P., Chua W., Loukogeorgakis S., et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366 (2005) 2026-2033
162. Agodoa L.Y., Appel L., Bakris G.L., et al., African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
163. Gifford Jr. R.W., August P.A., Cunningham G.A., et al. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 183 (2000) S1-S22
164. Caritis S., Sibai B., Hauth J., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 338 (1998) 701-705
165. Levine R.J., Hauth J.C., Curet L.B., et al. Trial of calcium to prevent preeclampsia. N Engl J Med 337 (1997) 69-76
166. Duley L., Henderson-Smart D.J., Knight M., et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev (2004) CD004659
167. Haukkamaa L., Salminen M., Laivuori H., et al. Risk for subsequent coronary artery disease after preeclampsia. Am J Cardiol 93 (2004) 805-808
168. Wilson B.J., Watson M.S., Prescott G.J., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life. Results from a cohort study. BMJ 326 (2003) 845
169. Falkner B., Roccella E., Daniels S.R., et al., National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 114 (2004) 555-576
170. Vaughan C.J., and Delanty N. Hypertensive emergencies. Lancet 356 (2000) 411-417
171. Elliott W.J. Clinical features and management of selected hypertensive emergencies. J Clin Hypertens (Greenwich) 6 (2004) 587-592
172. Murphy M.B., Murray C., and Shorten G.D. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345 (2001) 1548-1557
173. Nienaber C.A., and Eagle K.A. Aortic dissection: new frontiers in diagnosis and management. Part II: therapeutic management and follow-up. Circulation 108 (2003) 772-778
174. Brott T., and Bogousslavsky J. Drug therapy: treatment of acute ischemic stroke. N Engl J Med 343 (2000) 710-722
175. Schrader J., Luders S., Kulschewski A., et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34 (2003) 1699-1703
176. Elliott W.J. Hypertensive urgencies. In: Bakris G.L. (Ed). The Kidney and Hypertension (2004), Martin Dunitz Publishers, London 139-152
177. Grossman E., Ironi A.N., and Messerli F.H. Comparative tolerability profile of hypertensive crises treatments. Drug Safety 19 (1998) 99-122
178. Garg J.P., Elliott W.J., Folker A., et al., RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 18 (2005) 619-626
179. Feigin V., Ratnasabapathy Y., and Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?. J Neurol Sci 229-230 (2005) 151-155